English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduRandy D. Blakely, Ph.D., has been named a Fellow of the American Society for Pharmacology and Experimental Therapeutics (ASPET). Designation as an ASPET Fellow recognizes leaders in the field for their exceptional contributions to pharmacological research, education, mentorship and leadership.
Tag: Serotonin
Psilera receives positive preclinical in vivo data for frontotemporal dementia (FTD) candidate, PSIL-006
Psilera, Inc. (Psilera), a leading biotechnology company developing therapies for rare neurological disorders, has received initial toxicity readouts from maximum tolerated dose (MTD) in vivo studies showing a strong safety profile.
Studying how serotonin alters locust’s sense of smell
Researchers at Washington University in St. Louis study the role of serotonin in altering odor driven behavioral and neural responses in locusts.
Weight gain is kicked to the curb in antipsychotic drug breakthrough
World first research from the University of South Australia shows that antipsychotics can be reformulated with a strategically engineered coating that not only mitigates unwanted weight gain but also boosts serotonin levels by more than 250%.
Mount Sinai Scientists Unravel How Psychedelic Drugs Interact with Serotonin Receptors to Potentially Produce Therapeutic Benefits
Researchers at the Icahn School of Medicine at Mount Sinai have shed valuable light on the complex mechanisms by which a class of psychedelic drugs binds to and activates serotonin receptors to produce potential therapeutic effects in patients with neuropsychiatric disorders such as depression and anxiety.
First-in-humans discovery reveals brain chemicals working behind the scenes during decision-making
The idea that people make decisions based on social context is not a new one in neural economic games. But now, for the first time, researchers publishing in Nature Human Behavior show the impact of the social context may spring from the dynamic interactions of dopamine and serotonin. Researchers built carbon-fiber electrodes that were implanted in patients receiving Deep Brain Stimulation surgery. The method allows researchers to measure more than one neurotransmitter at a time, revealing a dance that has never been seen before
Scientists reveal structures of neurotransmitter transporter
Scientists at St. Jude Children’s Research Hospital determined structures of a transporter protein involved in the movement of neurochemicals such as serotonin and dopamine, unearthing multiple mechanisms that can guide drug development.
Happy worms have healthy eggs
Worms might not be depressed, per se. But that doesn’t mean they can’t benefit from antidepressants.
FAU, Israel Scientists ‘Team Up’ to Tackle Alzheimer’s-related Mood Disorders
Researchers from Florida Atlantic University, in collaboration with Tel Aviv University, have received a two-year, $379,177 grant from the National Institute on Aging, National Institutes for Health, on a collaborative project to study mood-disorders changes in Alzheimer’s disease.
Study Indicates Neurosurgical Procedure Used to Measure Dopamine and Serotonin Is Safe
Scientists at Wake Forest University School of Medicine have demonstrated that a neurosurgical procedure used to research and measure dopamine and serotonin in the human brain is safe.
Their findings are published online in PLOS One, a journal published by the Public Library of Science.
Don’t throw away your antidepressants just yet
While the review has made headlines for “debunking” the serotonin imbalance theory, it is important not to jump to conclusions on the efficacy of antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs).
As science searches for answers on depression, what should patients do today?
Serotonin’s precise role in depression is getting attention because of a well-publicized new study, but SSRIs work for many people, as do other treatments. A depression expert explains why basic neuroscience research shouldn’t guide clinical decisions in real time.
McMaster scientists pinpoint key trigger of Crohn’s disease
Researchers gleaned their results by analyzing blood and biopsy samples from two groups totalling 18 people with Crohn’s disease, comparing them to a matching number of people from two healthy control groups. A mouse model of IBD was also used. Khan said his study was the first demonstration of the interaction between serotonin, autophagy and gut microbiota in intestinal inflammation. The paper was published by Science Advances today. Sabah Haq, a PhD student who works with Khan, is first author.
Mount Sinai Neurobiologist Selected as a Howard Hughes Medical Institute Investigator
The Howard Hughes Medical Institute (HHMI) has selected Ian Maze, PhD, Associate Professor of Neuroscience, and Pharmacological Sciences, at the Icahn School of Medicine at Mount Sinai, as an HHMI Investigator.
COVID-19 Blood Flow Changes May Be Reason for ‘Brain Fog,’ Depression
A new review suggests that blood vessel damage and impaired oxygen delivery related to COVID-19 play a role in mood changes and cognitive difficulties that people with the disease face during illness and recovery. The review is published in Physiological Reports.
Researchers engineer “gut feeling” in a lab dish
Research into the gut-brain axis continues to reveal how the brain and gut influence each other’s health and well-being. Now researchers are endeavoring to learn more about gut-brain discourse using a model system built in a lab dish.
Scientists find neurochemicals have unexpectedly profound roles in the human brain
Dopamine and serotonin are at work at sub-second speeds to shape how people perceive the world and take action based on their perception. The discovery shows researchers can simultaneously measure the activity of both dopamine and serotonin in disorders ranging from depression to Parkinson’s disease.